)
Visual
test
Cytek Biosciences
Cytek Biosciences (CTKB) investor relations material
Cytek Biosciences 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Company achievements and market position
Recognized as a leading cell analysis company, named among the fastest growing by TIME and awarded for innovation and drug discovery solutions in 2025.
Shipped over 3,400 instruments to more than 2,000 unique customers in 70+ countries since 2016.
2024 and preliminary 2025 revenue reached $201 million, with $262 million in cash and marketable securities as of September 2025.
Revenue distribution: 50% U.S., 26% EMEA, 24% APAC/ROW; 59% from biotech/pharma/distribution, 41% from academia/government.
Market opportunity projected to grow from $5.1 billion in 2025 to $9.2 billion by 2032 at 8.8% CAGR.
Business pillars and technology innovation
Five business pillars: instruments, applications, bioinformatics, clinical, and services.
Continuous investment in instrument performance, intelligence, and data harmonization.
Cytek Cloud user base grew 40% in 2025, surpassing 22,600 users and supporting automated panel design.
Clinical instruments approved in China and Europe, with improved sensitivity for MRD applications.
AI-driven data analysis and harmonization enhance clinical and research applications.
Product portfolio and growth drivers
Broad portfolio includes conventional, full spectral, and imaging-based flow cytometry tools.
Aurora Evo, launched in 2024, offers high throughput and advanced features, driving replacement cycles.
Reagent business expanded post-2021 acquisition of Tonbo; 2024 reagent revenue grew over 20%, and Q3 2025 reagent revenue grew ~21%.
Acquired Luminex assets in 2023 to enter imaging space and formed partnerships with Bio-Rad and Luminex.
Service and reagent revenue, plus APAC instrument sales, comprise 50% of business and grew double digits in 2024; recurring revenue base continues to expand.
Penetration strategy for low/mid-end market
Clinical strategy for US market growth
Cytek Cloud's competitive advantage
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- OSUN
Floating solar project certified, NOK 9.9M raised, Q4 net loss NOK 4.4M, 36 MWp pipeline. - 543220
Strong revenue and profit growth in Q3 FY26, driven by expansion and digital gains. - AKTIA
Strong Q4, life insurance up 24%, EUR 70.1M impairment, CET1 ratio at 12.6% for year-end. - RÖKO
Net sales and profit rose, margins improved, and three acquisitions and an IPO were completed. - PNDORA
2025 organic growth was 6% with 23.9% EBIT margin; 2026 outlook remains cautious. - MARKSANS
Quarterly revenue and profit rose year-over-year, supported by global expansion and strong cash flow. - NEWA
Record revenue above SEK 10 billion, solid growth, and a SEK 3.00 dividend proposed. - 513023
Quarterly profit surged on strong mining and energy results, despite ongoing receivable risks. - GODREJPROP
Record Q3 FY26 bookings, strong profit growth, and robust margins with one-time labour cost impact. - 507717
Quarterly net profit reached ₹3,999.54 lakhs, with key board and committee changes approved.
Next Cytek Biosciences earnings date
Q4 202525 Feb, 2026
Cytek Biosciences
Next Cytek Biosciences earnings date
Q4 202525 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cytek Biosciences Inc. is a biotechnology company specializing in cell analysis solutions. The company develops and manufactures flow cytometry instruments, reagents, and software used in biomedical research and clinical diagnostics. Cytek’s technologies enable the study of cell characteristics, functions, and biomarkers, supporting research in immunology, oncology, and other areas of life sciences. The company serves academic institutions, pharmaceutical companies, and clinical laboratories, providing tools for advanced cellular analysis and discovery. The company is headquartered in Fremont, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage